LIGAND PHARMACEUTICALS INCORPORATED Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements of $8.83 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2015-06-30 was $93.00K, a 73.80% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2015-03-31 was $297.00K, a 7.61% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2024 was $8.83M.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2017 was $870.00K, a 304.65% increase from fiscal 2016.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2016 was $215.00K, a 44.87% decline from fiscal 2015.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $8.83M 10-K · filed 2026-02-27 | ||||
| 2018-12-31 | $0.00 10-K · filed 2019-02-28 | ||||
| 2017-12-31 | $870.00K 10-K · filed 2018-03-01 | ||||
| 2016-12-31 | $215.00K 10-K · filed 2017-02-28 | ||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-11-14 | $0.00 derived: sum of 2 quarters · filed 2016-11-14 | $93.00K derived: sum of 3 quarters · filed 2016-11-14 | $390.00K 10-K · filed 2016-11-14 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $93.00K derived: sum of 2 quarters · filed 2015-11-09 | $390.00K 10-Q · filed 2015-11-09 | $631.00K derived: sum of 4 quarters · filed 2015-11-09 | |
| 2015-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $390.00K 10-Q · filed 2015-08-05 | $631.00K derived: sum of 3 quarters · filed 2015-08-05 | $1.00M derived: sum of 4 quarters · filed 2015-08-05 | |
| 2015-03-31 | $297.00K 10-Q · filed 2015-05-11 | $538.00K derived: sum of 2 quarters · filed 2015-05-11 | $909.00K derived: sum of 3 quarters · filed 2015-05-11 | $1.26M derived: sum of 4 quarters · filed 2015-05-11 | |
| 2014-12-31 | $241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-23 | $612.00K derived: sum of 2 quarters · filed 2015-02-23 | $967.00K derived: sum of 3 quarters · filed 2015-02-23 | $1.24M 10-K · filed 2015-02-23 | $3.31M 10-K · filed 2014-12-01 |
| 2014-09-30 | $371.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | $726.00K derived: sum of 2 quarters · filed 2014-10-31 | $1.00M 10-Q · filed 2014-10-31 | $1.86M derived: sum of 4 quarters · filed 2014-12-12 | |
| 2014-06-30 | $355.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $631.00K 10-Q · filed 2014-08-05 | $1.49M derived: sum of 3 quarters · filed 2014-12-12 | $2.25M derived: sum of 4 quarters · filed 2014-12-12 | |
| 2014-03-31 | $276.00K 10-Q · filed 2014-05-07 | $1.14M derived: sum of 2 quarters · filed 2014-12-12 | $1.90M derived: sum of 3 quarters · filed 2014-12-12 | $2.73M derived: sum of 4 quarters · filed 2014-12-12 | |
| 2013-12-31 | $860.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2014-12-12 | $1.62M derived: sum of 2 quarters · filed 2014-12-12 | $2.46M derived: sum of 3 quarters · filed 2014-12-12 | $3.31M 10-K/A · filed 2014-12-12 | |
| 2013-09-30 | $761.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $1.60M derived: sum of 2 quarters · filed 2013-11-08 | $2.45M 10-Q · filed 2013-11-08 | ||
| 2013-06-30 | $836.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $1.69M 10-Q · filed 2013-08-01 | |||
| 2013-03-31 | $853.00K 10-Q · filed 2013-05-08 | ||||
| 2012-12-31 | $3.48M 10-K · filed 2013-03-14 | ||||
| 2011-12-31 | $4.16M 10-K · filed 2013-03-14 |